Ni Yue-Nan, Luo Jian, Yu He, Liu Dan, Ni Zhong, Cheng Jiangli, Liang Bin-Miao, Liang Zong-An
Department of Respiratory and Critical Care Medicine, West China School of Medicine and West China Hospital, Sichuan University, Sichuan, China.
Department of Critical Care Medicine, West China School of Medicine and West China Hospital, Sichuan University, Sichuan, China.
Chest. 2017 Apr;151(4):764-775. doi: 10.1016/j.chest.2017.01.004. Epub 2017 Jan 13.
The effects of high-flow nasal cannula (HFNC) on adult patients with acute respiratory failure (ARF) are controversial. We aimed to further determine the effectiveness of HFNC in reducing the rate of endotracheal intubation in adult patients with ARF by comparison to noninvasive positive pressure ventilation (NIPPV) and conventional oxygen therapy (COT).
The PubMed, Embase, Medline, and the Cochrane Central Register of Controlled Trials databases, as well as the Information Sciences Institute Web of Science, were searched for all controlled studies that compared HFNC with NIPPV and COT in adult patients with ARF. The primary outcome was the rate of endotracheal intubation; the secondary outcomes were ICU mortality and length of ICU stay.
Eighteen trials with a total of 3,881 patients were pooled in our final studies. Except for ICU mortality (I = 67%, χ = 12.21, P = .02) and rate of endotracheal intubation (I = 63%, χ = 13.51, P = .02) between HFNC and NIPPV, no significant heterogeneity was found in outcome measures. Compared with COT, HFNC was associated with a lower rate of endotracheal intubation (z = 2.55, P = .01) while no significant difference was found in the comparison with NIPPV (z = 1.40, P = .16). As for ICU mortality and length of ICU stay, HFNC did not exhibit any advantage over either COT or NIPPV.
In patients with ARF, HFNC is a more reliable alternative than NIPPV to reduce the rate of endotracheal intubation than COT.
高流量鼻导管吸氧(HFNC)对成年急性呼吸衰竭(ARF)患者的影响存在争议。我们旨在通过与无创正压通气(NIPPV)和传统氧疗(COT)比较,进一步确定HFNC在降低成年ARF患者气管插管率方面的有效性。
检索了PubMed、Embase、Medline、Cochrane对照试验中心注册库数据库以及信息科学研究所的科学网,以查找所有比较HFNC与NIPPV和COT用于成年ARF患者的对照研究。主要结局是气管插管率;次要结局是重症监护病房(ICU)死亡率和ICU住院时间。
我们的最终研究汇总了18项试验,共3881例患者。除了HFNC与NIPPV之间的ICU死亡率(I=67%,χ=12.21,P=.02)和气管插管率(I=63%,χ=13.51,P=.02)外,结局指标未发现显著异质性。与COT相比,HFNC与较低的气管插管率相关(z=2.55,P=.01),而与NIPPV相比未发现显著差异(z=1.40,P=.16)。至于ICU死亡率和ICU住院时间,HFNC与COT或NIPPV相比均未显示出任何优势。
在ARF患者中,与COT相比,HFNC是比NIPPV更可靠的降低气管插管率的替代方法。